title: Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia.
abstract: Uni-rhinal olfactory acuity in schizophrenia was investigated in two experiments. The first assessed the presence of a predicted atypical asymmetry of nostril laterality and the second assessed the effect of antipsychotic treatment on the asymmetry. Although olfactory identification impairment has been well documented in schizophrenia, olfactory acuity has been neglected. This may be an oversight as cerebral structures of the mesial temporal lobe important to olfactory perception have often been implicated in the pathophysiology of schizophrenia and it is thus reasonable to postulate a primary impairment of olfactory acuity in schizophrenia. In addition, unmedicated patients with schizophrenia have exhibited asymmetrical laterality favouring the right over the left hemisphere in studies of visual, haptic, and auditory perception, and the few published prospective treatment studies have suggested a reversal of this asymmetry with first generation neuroleptic treatments. In experiment 1 a generalization of the perceptual asymmetry to olfactory acuity was examined by measurement of n-butanol olfactory thresholds with the Connecticut Chemosensory Perception Exam (CCPE) in an unmedicated sample of 17 patients with schizophrenia and 17 age, gender, and handedness matched normal controls. The patient sample showed an asymmetrical impairment of the left nostril that was not apparent in the normal control sample. In experiment 2, the CCPE was administered to a new sample of 10 patients with schizophrenia before and after neuroleptic treatment. The asymmetry observed in experiment 1 was replicated, and the relative advantage of the right nostril shifted to a relative advantage of the left nostril over the course of 8weeks of treatment. Results are discussed in relation to cerebral aspects of schizophrenia and potential implications to cognitive change from treatment.
authors.affiliation: Alberta Hospital Edmonton, Box 307, Edmonton, T5J 2J7, Alberta, Canada. scot.Purdon@Amhb.ab.ca
authors.forename: S E
authors.initials: SE
authors.lastname: Purdon
authors.forename: P
authors.initials: P
authors.lastname: Flor-Henry
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D007839:Functional Laterality / Q000187:drug effects; D006801:Humans; D008297:Male; D000857:Olfaction Disorders / Q000150:complications*; D011446:Prospective Studies; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy*; D012684:Sensory Thresholds / Q000187:drug effects*; D012903:Smell / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents